GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2008

ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development

  • ImmunoVaccine Technologies (IVT) will obtain C$3 million from the Atlantic Canada Opportunities Agency (ACOA) to develop new potent immune enhancement systems. The funding was received under the Atlantic Innovation Fund. The work will be a part of a C$6 million project.

    “This funding will enable us, over the next three years, to create novel vaccines for the treatment of cancer and infectious diseases,” comments Brian Lowe, vp. IVT also says that the financing will further its research collaborations and commercialization opportunities with pharmaceutical companies worldwide.

    IVT developed a vaccine-enhancement technology called the VacciMax®. It comprises a mixture of liposomes and adjuvants. The platform is able to stimulate an earlier, more powerful, long-lasting immune response that could provide a new way to treat a wide range of diseases, according to the firm.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?